Distribution of Molecular Breast Cancer Subtypes in Middle Eastern-Saudi Arabian Women: A Pilot Study

REFERENCES

• Feuer EJ, et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892–897.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Pisani P eds. GLOBOCAN: cancer incidence and mortality worldwide. International Agency for Research on Cancer (IARC) Cancer Base 3, IARC Lyon, France 1998.
   Google Scholar
• Gulf center for cancer registration, the Research Center; King Faisal Specialist Hospital and research Center. GCC: Breast cancer in the GCC countries 1998–2002. Riyadh (Kingdom of Saudi Arabia): King Faisal Specialist Hospital and Research Center; 2004.
   Google Scholar
• Chanrion M, Fontaine H, Rodriguez C, et al. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. BMC Cancer. 2007;7:39.
   Google Scholar
• Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology. 2008;52:67–81.
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826.
   PubMed Web of Science ®Google Scholar
• Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.
   PubMed Web of Science ®Google Scholar
• Al-Kuraya K, Schramel P, Skeikh , et al. Predominance of high-grade pathway in breast cancer development of middle east women. Modern Pathology. 2005;18:891–897.
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS. 2003;100:8418–8423.
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–10398.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D. Gene expression profiling and clinical outcome in breast cancer. OMICS. 2006;10(4):429–443.
   Google Scholar
• Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374.
   PubMed Web of Science ®Google Scholar
• Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340–350.
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005;65:767–779.
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502.
   PubMed Web of Science ®Google Scholar
• Mullins M, Perreard L, Quackenbush JF, et al. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem. 2007;53:1273–1279.
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MCU, et al. A supervised risk predictor of breast cancer based on intrinsic subtypes. JCO. 2009;27(8):1160–1167.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59:225–231.
   PubMed Web of Science ®Google Scholar
• Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003;95:14–18.
   PubMed Web of Science ®Google Scholar
• Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537.
   PubMed Web of Science ®Google Scholar
• Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418–427.
   PubMed Web of Science ®Google Scholar
• Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA. 2006;103:5923–5928.
   PubMed Web of Science ®Google Scholar
• Megha T, Ferrari F, Benvenuto A, et al. p53 mutant in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol. 2002;55:461–466.
   Google Scholar
• Tang P, Wang X, Schiffhauer L, et al. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci. 2006;36:16–22.
   Google Scholar
• Tang P, Wang X, Schiffhauer L, et al. Expression patterns of ER-(α, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non–high grade ductal carcinoma in situ. Ann Clin Lab Sci. 2006;36:137–143.
   Google Scholar
• Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37:127–134.
   Google Scholar
• Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991–1996.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729–735.
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer. Cancer. 2007;109:25–32.
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)–negative, progesterone receptor (PR)–negative, and HER2-negative invasive breast cancer, the so called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer. 2007;109:1721–1728.
   PubMed Web of Science ®Google Scholar
• Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and pcadherin: three molecular markers to distinguish basal pheno-type in breast carcinomas. Virchows Arch. 2005;477:688–694.
   Google Scholar
• Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–271.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Charafe-Jauffret E, Bertucci F, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161:1223–1233.
   PubMed Web of Science ®Google Scholar
• Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142–153.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–5685.
   PubMed Web of Science ®Google Scholar
• Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34.
   PubMed Web of Science ®Google Scholar
• Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen receptor-negative breast cancers. Breast Cancer Res. 2007;9:R16.
   Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236–240.
   PubMed Web of Science ®Google Scholar
• Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and end results database. Cancer. 2007;110:876–884.
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohisto-chemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108–118.
   PubMed Web of Science ®Google Scholar
• Bin Amer SN, Magbool Z, Nirmal MS, et al. Gene expression profiling in women with breast cancer in Saudi population. . 2008;29:507–513.
   Google Scholar